Göttingen, Germany (ots/PRNewswire) – – Albumedix Ltd. based in England, is a leading provider of recombinant albumin-based solutions and a highly innovative and profitable company
– Recombinant human albumin is a key building block in the production of innovative biopharmaceuticals, particularly for modalities such as cell therapies, viral therapies and vaccines
– Sartorius to acquire 100 percent of Albumedix for approximately 415 million British pounds
The life science group Sartorius, through its French-listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of the shares of Albumedix Ltd. which had previously been held by private investors. The company, founded in 1984 and headquartered in Nottingham, England, is a provider of industry-leading solutions based on recombinant albumin. Recombinant human albumin is a key building block for the biopharmaceutical industry and is required for a range of applications, for example as an animal cell-free additive for cell culture media and for stabilizing vaccines and viral therapies. Albumedix has more than 100 employees and is expected to generate revenues of approximately £33 million in 2022 with a significant double-digit EBITDA margin. The agreed purchase price is approximately 415 million British pounds. The transaction, which is subject to regulatory approvals, is expected to close before the end of the third quarter of 2022.
“Albumedix is an important addition to Sartorius’ Advanced Therapies solution offering. This is especially true with regard to our cell culture media business, where Albumedix will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical components. This market offers high growth potential due to increasing regulatory requirements and the growing demand for recombinant human albumin in near-patient applications. With Albumedix, we are also adding important formulation aids to our vaccine production solution offering, enabling us to expand existing customer relationships and win new ones,” said René Fáber, Executive Board member for Sartorius’ Bioprocess Solutions Division.
“We are very pleased to join forces with Sartorius and accelerate our ambitious growth plans, the foundation of which is to offer important solutions to our customers worldwide. We are impressed by Sartorius’ knowledge and capabilities in the bioprocess markets and look forward with great confidence to our future journey together. We are convinced that Sartorius will make a major contribution to strengthening our market presence, expanding our innovation capabilities and significantly growing our existing platform. We remain focused on our promise to enable excellence in the life science industry,” said Jonas S. Møller, CEO of Albumedix.
Albumedix will become part of Sartorius’ Bioprocess Solutions division. The plan is to establish the existing 6,700 sq. ft. site in Nottingham as a center of excellence, innovation and GMP-compliant production for critical ingredients.
Milbank LLP provided legal advice to Sartorius on this transaction. William Blair acted as financial advisor and Eversheds Sutherland as legal advisor to Albumedix.
This publication contains statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. Sartorius assumes no obligation to update such statements in light of new information or future events.
Sartorius in Brief
The Sartorius Group is a leading international partner to biopharmaceutical research and industry. The Lab Products & Services Division focuses on research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies and academic research institutions with innovative laboratory instruments and consumables. The Bioprocess Solutions division helps to ensure that biotech drugs and vaccines are manufactured safely and efficiently with a broad product portfolio focused on single-use solutions. The Group is growing at an average double-digit rate per year and regularly supplements its portfolio with acquisitions of complementary technologies. In fiscal 2021, the company generated sales of around EUR 3.45 billion. At the end of 2021, almost 14,000 employees were working for customers around the globe at the Group’s approximately 60 production and sales sites.
Logo – https://mma.prnewswire.com/media/1696516/Sartorius_Logo.jpg
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
Head of External Communications
Head of Investor Relations
OTS-ORIGINAL TEXT PRESS RELEASE UNDER EXCLUSIVE CONTENT RESPONSIBILITY OF THE SENDER. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH and the respective sender
The post Sartorius acquires Albumedix and strengthens its portfolio of innovative solutions for advanced therapies appeared first on TOP News Austria – News from Austria and around the world.